Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Citigroup reported Q3 results on October 13 and the stock's reaction reignited the same post-earnings pattern that played out in July: a sharp one-day fall followed by analysts marking down targets across the board.
The price damage was immediate. Citi closed at $124.53 on October 13, down 5.6% on the day and off 10.3% over the past month. That mirrors the July print almost exactly, when the stock fell 4.1% on the day and 5.6% over the following week. Peers traded down too, but by far less. WFC fell 3.1% on the day. BAC dropped 1.1%. JPM was off less than 1%. Citi's move was clearly stock-specific, not a sector-wide de-rating.
The Street's response was swift and in one direction. Three analysts cut targets on October 14. Evercore ISI's Glenn Schorr lowered from $140 to $135 while keeping an In-Line rating. RBC Capital's Gerard Cassidy trimmed from $150 to $135, holding Outperform. TD Cowen's R. Scott Siefers, who had reinstated coverage with a Buy and a $150 target just six days earlier, cut to $148. All three maintained their ratings, so the message is recalibration rather than retreat. The mean target now sits at $134, above the current price, but the gap has narrowed sharply from where it stood a week ago. Bulls point to the restructuring delivering real earnings power: Q2 EPS of $3.15, net interest income of $17.1 billion, and a 7.1% rise in tangible book value per share. Bears flag that advisory revenue fell 23% in that quarter, non-interest revenue in that segment stayed deeply negative, and provisions of $2.5 billion still represent a meaningful drag on returns. The ROTCE target of 14% to 15% remains the central test, and the Q3 print appears to have raised fresh doubts about the pace of getting there.
Options positioning has actually turned less defensive than usual, despite the sell-off. The put/call ratio is at 1.30, nearly two standard deviations below its 20-day average of 1.36. That is close to the 52-week low of 0.88, and well below the high of 1.43. Short interest offers no squeeze angle: at 1.2% of the free float and falling 14% over the past week, bears have been covering, not adding. Borrow availability is effectively unlimited, with the lending pool nowhere near stressed. This is not a positioning story. It is a fundamentals-and-execution story, and the options market is not particularly alarmed.
Two FDIC call-report facts from the alt data are worth noting as context, not as a forecast of the print. Net loans and leases at Citi's insured bank charters have risen for nine consecutive quarters, reaching $739.5 billion as of the April 2026 period. Total deposits have risen for six consecutive quarters, reaching $1.55 trillion. Neither dataset has yet been tested as a leading indicator for reported figures, so they describe balance-sheet momentum rather than point to a specific outcome.
The ORTEX short score has edged down to 29.6 from 30.4 at the start of the week, consistent with the short-covering trend. Factor scores are supportive on EPS momentum and surprise, ranking in the 77th and 83rd percentiles respectively, but the 12-month forward EPS growth score is only in the 43rd percentile, reflecting the market's uncertainty about the pace of earnings improvement. The price-to-book multiple has compressed to just above 1.0x, down about 9% over the past month. At that level, the stock is effectively trading at book value, a floor that bulls argue limits downside but that bears note has not historically been sufficient on its own to drive re-rating without a credible ROTCE path.
What to watch next is whether analysts who held ratings this week follow through with actual downgrades, and whether the Q3 print's specific revenue line items, particularly in Banking and Wealth, support or further complicate the management case for reaching 14% to 15% ROTCE by the targets previously communicated.
See the live data behind this article on ORTEX.
Open C on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
